Gilead released data showing that an HIV drug, called lenacapavir, could provide virtually complete protection against ...

Gilead has reported results for a once-yearly intramuscular injection that show blood concentrations of lenacapavir exceeded ...

Bay Area drug giant Gilead is plotting the trial of a groundbreaking, once-a-year HIV prevention drug lenacapavir.

An annual shot to protect against HIV infection has successfully passed an early safety trial, according to research ...

Utilizing syringe service programs to provide comprehensive PrEP care shows promise for encouraging more people who inject ...

Several health advocacy and LGBTQ organizations are urging the United States Supreme Court to uphold coverage and zero ...

A yearly injection such as Lenacapavir could help overcome barriers to PrEP accessibility by increasing its uptake and making ...

An end-to-end digital PrEP pathway appeared to improve accessibility, inclusivity, and service satisfaction among LGBTQ+ ...

Lenacapavir, which stops HIV from replicating inside cells, has passed early safety tests.